IBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
IBIO, INC. (IBIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $1.20 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-28
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2019-03-31 was $46.00K.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2026 was $1.20M, a 20.17% decline from fiscal 2025.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $1.51M.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $4.83M, a 44.81% increase from fiscal 2022.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $3.33M, a 265.97% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|
| 2026-06-30 | $1.20M 10-K · filed 2026-08-28 | ||
| 2025-06-30 | $1.51M 10-K · filed 2026-08-28 | ||
| 2023-06-30 | $4.83M 10-K · filed 2023-09-27 | ||
| 2022-06-30 | $3.33M 10-K · filed 2023-09-27 | ||
| 2021-06-30 | $911.00K 10-K · filed 2022-10-11 | ||
| 2020-06-30 | $433.00K 10-K · filed 2021-09-28 | $242.00K 10-Q · filed 2020-05-15 | |
| 2019-06-30 | $57.00K 10-K · filed 2020-10-13 | $571.00K 10-Q · filed 2018-11-13 | |
| 2019-03-31 | $46.00K 10-Q · filed 2019-05-10 | ||
| 2018-06-30 | $972.00K 10-K · filed 2019-08-26 | ||
| 2017-06-30 | $1.24M 10-K · filed 2018-09-18 | ||
| 2016-06-30 | $800.00K 10-K · filed 2017-09-15 | ||
| 2015-06-30 | $1.10M 10-K · filed 2016-10-13 | ||
| 2014-06-30 | $900.00K 10-K · filed 2015-10-13 | $1.10M 10-K · filed 2014-09-29 | |
| 2013-06-30 | $2.50M 10-K · filed 2014-09-29 | ||
| 2012-06-30 | $700.00K 10-K/A · filed 2013-10-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |